A single-dose of KD033-surrogate showed increased efficacy when compared to repeat doses of anti-PD-L1 alone, or the highest tolerated dose of the non-targeting IL-15 in the murine CT26 colon carcinoma model [8]. This evidence concerns the gene CD274 and colon carcinoma.